"First half in line" is not usually a phrase that sends a share price tumbling. Yet that is roughly what happened to Spirax Group on 11 August 2026, when the steam, electric heating and pump specialist published its half-year results. Growth was solid, profits rose and full-year guidance was left unchanged, but the market focused on something else.
Spirax Group (LSE:SPX), a FTSE 100 constituent, reported 5% organic Revenue growth and reiterated its 2026 guidance. The shares still fell sharply on the day, by around 10%, although reports differed on the exact size of the drop. The main concern was weak cash generation in the first six months of the year.
Solid Growth, Unchanged Outlook
On the surface, the half-year statement read well. Revenue reached £863.8m, up 5% on both an organic and reported basis. That was well ahead of global industrial production, which the company said grew 1.5% outside China over the period, and Spirax has long measured itself against that benchmark.
Chief executive Nimesh Patel said the group had "again delivered resilient mid-single-digit organic growth in revenue and profit, well ahead of IP". He pointed to continuing momentum in semiconductor and biopharmaceutical markets, along with strong order books, as support for second-half growth. Spirax reiterated full-year guidance for mid-single-digit organic revenue growth and organic expansion of its adjusted Operating Margin from 2025's 20.0%.
Where the Numbers Disappointed
Adjusted operating profit rose 6% organically to £171.1m, giving an adjusted operating margin of 19.8%, up 10 basis points on an organic basis. Adjusted Earnings Per Share increased 9% to 150.0p. Statutory operating profit jumped 44% to £154.2m, flattered by restructuring charges in the prior year. The Interim Dividend was raised 3% to 50.4p.
Cash was the weak spot. Adjusted cash from operations was £91.6m, and cash conversion fell 700 basis points to 54%. Adjusted free Cash Flow came to only £37.3m. Spirax blamed planned inventory builds and normal seasonal swings in working capital, but for a company prized for its cash generation, the figure stood out.
Leverage was also slightly above target. Net Debt to EBITDA was 1.6 times, above the group's preferred range of 1.0 to 1.5 times. Combined with a weaker cash performance, that gave the market reason to question how quickly debt will come down.
A Tale of Three Businesses
The divisional picture was mixed. Steam Thermal Solutions, the largest business, grew revenue just 1% organically to £419.8m, and its margin fell 170 basis points to 22.0% as the company invested in the first half. China sales fell 1%, a smaller decline than the 6% drop a year earlier.
Electric Thermal Solutions was the standout. Revenue rose 11% organically to £232.9m and its margin improved by 220 basis points to 17.2%, helped by double-digit growth in semiconductor demand. Semiconductor customers made up 13% of the division's sales in 2025. Watson-Marlow Fluid Technology Solutions grew 7% organically to £211.1m with a 27.5% margin. Biopharma orders reached their highest quarterly level since the Covid-era peak in 2021.
This matters for the bigger picture. Spirax has spent years trying to show that it can grow faster than the industrial economy through its Together for Growth strategy. Exposure to semiconductors, data centres, biopharma and decarbonisation gives it structural growth themes, and the company estimates decarbonisation solutions add around £7bn to its addressable market. Returns also improved, with return on capital employed rising 180 basis points to 35.2% and return on invested capital up 90 basis points to 13.3%. The group, formerly known as Spirax-Sarco Engineering, operates more than 30 Manufacturing plants and employs over 10,000 people across around 70 countries.
The Risks Behind the Reaction
The share price fall highlights how high expectations can be for a company with a long record of steady performance. Guidance relies on a stronger second half. Steam Thermal Solutions must deliver better margins on higher shipments, while Electric Thermal and Watson-Marlow are both expected to post high-single-digit sales growth in the second half.
The wider backdrop is not especially supportive. Spirax noted that industrial production remains subdued in key markets, including Germany, where it contracted, and the US and France, where growth was slight. Forecasters expect global industrial production growth of just 1.9% for 2026. If customers delay maintenance or projects, the steam Business in particular could feel it.
Cash is the other watchpoint. If the inventory build does not unwind as planned in the second half, the free cash flow figure will stay under pressure and Leverage may remain above target for longer. Costs are also rising in places, with corporate costs expected to be higher than in 2025 because of Investment in digital and services, and ramp-up costs at a new medium voltage Facility in Ogden in the US.
What Comes Next for Spirax
The key test is the second half. Investors will look for a recovery in cash conversion, a better margin in Steam Thermal Solutions and continued strength in semiconductor and biopharma orders. Any sign that guidance for mid-single-digit growth and margin expansion is slipping would be closely watched.
Full-year results, which Spirax usually publishes in early March, will provide the answer on cash and leverage. In the meantime, news on industrial production in Europe, the US and China will offer clues about demand. The company has also said it remains on track to deliver the medium-term targets set in October 2024.
Divisional guidance gives further markers. Spirax expects Steam Thermal Solutions' full-year margin to be broadly in line with 2025, reflecting investment weighted to the first half. Electric Thermal Solutions is expected to post a second-half margin slightly ahead of the first half, and Watson-Marlow a margin broadly similar to the first half. Progress against each of those markers will show whether the second-half recovery is on track.
Conclusion
Spirax's half-year results showed a business still growing faster than its markets, with strong semiconductor and biopharma Demand and guidance intact. The market's sharp reaction was driven by weak cash conversion, higher leverage and a heavy reliance on the second half. Whether that reaction proves an overreaction depends on how cash flow and the steam business perform in the rest of 2026.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...